
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is positioned for success with its first-in-class oral therapy for inflammatory bowel diseases, obefazimod, which has demonstrated best-in-disease efficacy in Phase 2 trials. With a favorable safety profile and promising data from Phase 3 trials, the company is on track for potential approval in 2026. Upside optionality in combination therapy, Crohn's Disease, and potential in other indications only add to the positive outlook for this biotech company.
Bears say
Abivax is a company focused on developing therapeutics for chronic inflammatory diseases. However, its sales and earnings potential are limited due to its single operating segment and early-stage drug development. There may also be market skepticism over the effectiveness and safety of obefazimod, as demonstrated by the high dropout rates in clinical trials, and potential competition from established treatments for inflammatory bowel diseases.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares